The European Medicines Agency’s interim report for 2012 suggests EMA is on course to meet its core business targets for the year. And, by revamping its approach to conflicts of interest and transparency, the agency says its budget will probably be approved by the European Parliament – meaning that EU funding in the longer term will not be held up.
Meanwhile, the European Commission’s input on redefining duplicate marketing authorizations has seen the collapse of generics applications at the agency.